In a report released on 03\/03\/2017 RBC Capital Markets bumped up the target of Stryker Corporation (NYSE:SYK) from $129.00 to $135.00 indicating a possible upside of 0.04%. <\/p>\n
Previously on 1\/25\/2017, Canaccord reported about Stryker Corporation (NYSE:SYK) increased the target price from $127.00 to $137.00. At the time, this indicated a possible upside of 0.13%. <\/p>\n
Yesterday Stryker Corporation (NYSE:SYK) traded -0.20% lower at $130.24. Stryker Corporations 50-day average is $124.46 and its two hundred day average is $117.54. With the last stock price up 11.27% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. Trade Volume was down over the average, with 940,446 shares of SYK changing hands under the typical 1,320,280 <\/p>\n<\/p>\n
With a total market value of $0, Stryker Corporation has price-earnings ratio of 30.07 with a one year low of $98.00 and a one year high of $131.36 . <\/p>\n
A total of 24 analysts have released a research note on SYK. Nine analysts rating the company a strong buy, eight analysts rating the company a buy, nine analysts rating the company a hold, two analysts rating the company a underperform, and finally 1 firm rating the stock a sell with a consensus target price of $116.50. <\/p>\n
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties. <\/p>\n
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter. <\/p>\n
<\/p>\n
Read more: <\/p>\n
A report released today by RBC Capital Markets about Stryker Corporation (NYSE:SYK) ups the target price to $135.00 - Breaking Finance News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" In a report released on 03\/03\/2017 RBC Capital Markets bumped up the target of Stryker Corporation (NYSE:SYK) from $129.00 to $135.00 indicating a possible upside of 0.04%. Previously on 1\/25\/2017, Canaccord reported about Stryker Corporation (NYSE:SYK) increased the target price from $127.00 to $137.00. Continue reading